DEB-TACE Plus Camrelizumab and Apatinib Versus DEB-TACE Plus Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma: a Multi-center, Prospective, Randomized, Clinical Trials

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100051197

Enrollment

Unknown

Registered

2021-09-15

Start date

2021-09-01

Completion date

Unknown

Last updated

2022-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Interventions

Experimental group:DEB-TACE+Camrelizumab+Apatinib

Control group:DEB-TACE+Camrelizumab

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Voluntarily participate in this study and sign the informed consent; 2. Aged >= 18 years, male or female; 3. HCC confirmed by histopathology, cytology or imaging (except fibrolamellar and mixed hepatocellular/cholangiocarcinoma subtypes); 4. Unresectable HCC determined by comprehensive evaluation; 5. Child-Pugh liver function rating: A-B ( 6; 8. Confirm at least one measurable HCC lesion according to RECIST v1.1 criteria; 9. Good organ function; 10. Other standards.

Exclusion criteria

Exclusion criteria: 1. Combined with Vp3 or Vp4 portal vein tumor thrombus and any large blood vessel tumor thrombus in other blood vessels; 2. Extrahepatic spread; 3. Diffuse or invasive liver cancer; 4. Currently a candidate for liver transplantation; 5. Previously received any systemic chemotherapy, including anti-VEGF therapy, or any systemic anticancer drugs for HCC; 6. Other standards.

Design outcomes

Primary

Measure	Time frame
Progression-free survival (PFS)by investigator according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Evaluation;	—

Secondary

Measure	Time frame
Overall survival;2. PFS by investigator according to modified Response Evaluation Criteria in Solid Tumors (mRECIST);Objective Response Rate (ORR) by investigator according to RECIST 1.1;Disease Control Rate (DCR) by investigator according to RECIST 1.1;Duration of Response (DOR) by investigator according to RECIST 1.1;Duration of Response (DOR) by investigator according to RECIST 1.1;Time to Progression (TTP) by investigator according to RECIST 1.1;ORR by investigator according to mRECIST;DCR by investigator according to mRECIST;DOR by investigator according to mRECIST;TTP by investigator according to mRECIST;Safety;	—

Measure

Time frame

Overall survival;2. PFS by investigator according to modified Response Evaluation Criteria in Solid Tumors (mRECIST);Objective Response Rate (ORR) by investigator according to RECIST 1.1;Disease Control Rate (DCR) by investigator according to RECIST 1.1;Duration of Response (DOR) by investigator according to RECIST 1.1;Duration of Response (DOR) by investigator according to RECIST 1.1;Time to Progression (TTP) by investigator according to RECIST 1.1;ORR by investigator according to mRECIST;DCR by investigator according to mRECIST;DOR by investigator according to mRECIST;TTP by investigator according to mRECIST;Safety;

—

Countries

China

Contacts

Public ContactHan Guohong

Xi'an International Medical Center Hospital, Northwest University

13991969930@126.com+86 29 68301893

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026